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Abstract 
Aims: Published studies have challenged the cost-effectiveness of insulin glargine versus NPH 
insulins in Brazil with limited evidence of increased effectiveness despite considerably higher 
acquisition costs. However, still a controversy. Consequently, a need to address this. Methods: 
Retrospective cohort study of type 1 diabetes patients receiving insulin glargine in Brazil following 
NPH insulin who met the criteria.  Results: 580 patients were enrolled. HbA1c varied from 8.80 ± 
1.98% in NPH insulin users to 8.54 ± 1.88% after insulin glargine for six months, which is not 
clinically significant. Frequency of glycemic control varied from 22.6% with NPH insulin to 26.2% 
with insulin glargine. No statistically significant difference was observed between controlled and still 
uncontrolled groups for all analyzed factors including type and frequency of insulin use and 
carbohydrate counting. Conclusions: Limited differences between NPH insulins and insulin 
analogues in routine clinical care does not justify an appreciable cost difference.  
 
Keywords: Brazil; Comparative effectiveness research; Insulin glargine; longitudinal studies; NPH 
insulin; Type 1 diabetes. 
 
1.  Introduction 
 
Type 1 diabetes is a chronic disease resulting from the inability of the pancreas to produce insulin 
(1). In view of the natural history of type 1 diabetes, the use of insulin immediately after diagnosis is 
advocated to adequately treat these patients (2). The most widely used insulins are called NPH 
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insulins and fast-acting insulin (soluble insulin). However, in order to make the profile of injected 
insulins closer to physiological insulins, insulin analogues were created (insulin glargine and insulin 
detemir) which have a prolonged action. 
 
There are concerns though with the cost-effectiveness of long acting insulins versus NPH insulins 
especially where there are appreciable cost differences as currently seen in Brazil (3,4). Published 
studies including systematic reviews and reviews by health authorities have demonstrated no 
superiority of insulin glargine in terms of effectiveness and safety compared with NPH insulin (3±
11).  Other studies, however, have found the opposite. Raskin et al (2000) showed a greater efficacy 
of insulin  glargine in reducing HbA1c (12). Herwig et al. (2007), Schreiber et al. (2007) and Salemyr 
et al. (2011) also showed that patients with type 1 diabetes  using insulin glargine achieved a better 
response in terms of glycemic control and decreasing HbA1c when compared with those using NPH 
insulin (13±15).  The differences in the findings may reflect the study sponsors as seen in our recent 
meta analysis of cohort studies comparing the effectiveness of insulin  glargine versus NPH insulin 
(4).  
 
Consequently, in view of current controversies, we wished to undertake our own cohort study 
evaluating the effectiveness of insulin glargine versus NPH insulin for the treatment of patients with 
type 1 diabetes to support decision making for greater efficiency within our healthcare system. This 
study aimed to evaluate the effectiveness of insulin glargine compared with NPH insulin for patients 
with type 1 diabetes in routine clinical care within Brazil. 
 
2.  Materials and Methods 
 
2.1  Sample  
This study was conducted in accordance with the Declaration of Helsinki. A historical cohort was 
conducted from January 2011 to January 2015, including users of the Specialized Pharmaceutical 
Care Component (SPCC) of the Brazilian National Healthcare system (SUS) in Minas Grais, 
developed from the construction of a database of individuals with type 1 diabetes treatment, 
registered according to the Clinical Protocol and Therapeutic Guidelines (CPTG) for insulin glargine 
use in Brazil (16). Patients have to fulfil these criteria in order to have their insulin approved and 
reimbursed (17).   
 
To analyze the clinical effectiveness, individuals were compared with themselves in an analysis of 
HbA1c values before and after six months of using insulin glargine. In this way, each patient acted as 
their own control avoiding concerns with randomization in routine clinical care. 
 
Individuals who met the eligibility criteria were included in the cohort. These included (1) patients 
who had been diagnosed with type 1 diabetes or latent autoimmune diabetes in adults (LADA); (2) 
whose cases met the inclusion criteria described in the CPTG  (ESM Table 1); (3) were currently on 
NPH insulin and who had not used long-acting insulin analogues prior to the approved use of insulin 
glargine; (4) whose inclusion in the program was between January 2011 and January 2015; and (5) 
who had at least two renewal processes for insulin glargine evaluated by reviewers of SUS  
Collaborating Centre - Technology Assessment and Excellence in Health (CCATES). The SUS 
Collaborating Centre for Technology Assessment and Excellence in Health is part of the National 
Network for Technology Assessment in Health (REBRATS) in Brazil. CCATES has an institutional 
partnership with the Ministry of Health (MoH) and the Health Department of Minas Gerais. Among 
its many activities, CCATES undertakes the analysis of administrative and judicial requests for 
medicines medical procedures and devices and develops rapid advice on issues relevant to health for 
the MoH. Individuals who were excluded at the first request to administer of insulin glargine or 
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insulin detemir as part of SUS, or patients whose term renewal request had exceeded nine months 
from the last release date, were excluded. 
 
2.2 Study variables  
Outcomes were assessed from the following variables: (i) demographic variables - ethnicity, sex and 
age; (ii) clinical variables ± time with a diagnosis of  type 1 diabetes, age at diagnosis and reporting 
of comorbidities of individuals at baseline; (iii) treatment characteristics - type of treatment, 
carbohydrate counting, prescribed doses of insulin, administration frequency of NPH insulin and 
insulin glargine, insulin type and prescribed doses of rapid-acting insulin and/or ultrafast and (iv) 
laboratory results of HbA1c. 
 
Laboratory results of HbA1C were used for clinical effectiveness analysis, by comparison of the 
HbA1c values of each person after six months of insulin glargine use, with the reference values 
recommended in the literature for their age. For individuals between 6 and 18 years, HbA1c 
between 19 and 59 years, HbA1c DQGRYHU\HDUV+E$1c  (18) were considered 
controlled and the individuals who were outside this reference range values were considered 
uncontrolled. 
 
This study did not assess glucose fasting values, since this measure has low validation to assess the 
efficacy and effectiveness of medicines for diabetes  because of being susceptible to divergences 
with actual glycemic control (19). 
 
2.3 Statistical analysis  
Categorical variables were analyzed using absolute and relative frequencies and continuous variables 
as mean, median and standard deviation. The difference between the mean doses of NPH insulin and 
insulin glargine were compared using the T test for paired samples. To identify factors associated 
with glycemic control of individuals after six months using insulin glargine, Chi-square test of 
Pearson was conducted for categorical variables and an analysis of variance, One Way ANOVA, for 
continuous variables. In case of a statistically significant difference, Tukey's test was used for 
multiple comparisons. Variables were considered significant with p <0.05 in the multiple model. 
Statistical analysis was performed using the software SPSS® version 20 (SPSS Inc., Chicago, IL, 
USA). 
 
3. Results 
 
Individuals¶GHPRJUDSKLFDQGclinical characteristics All administrative processes scanned by 
CCATES were evaluated. In all 1,461 individuals, received long acting insulins from January 2011 to 
January 2015. 854 patients were subsequently registered for the study, according to the eligibility 
criteria. After analyzing administrative procedures, 580 patients were finally included in the study 
sample (Figure 1).  
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Figure 1 ± Study sample 
 
 
Total of individuals with administrative processes scanned 1461 
 
     
Total of individuals 
registered 
854 
 
      
Total of individuals included  580 
 
 
The sex distribution was similar, the predominant ethnicity was white (33.8%) and most individuals 
were between 20 and 59 years old (63.1%). 79% of patients did not report the presence of 
comorbidities associated with type 1 diabetes (ESM Table 2). 
 
The average age of participants was 33 years (SD = 17.3), with the average age at diagnosis of type 1 
diabetes being 17.5 years (SD = 13.2). At the end of the study, the average time of treatment of 
patients was 14.8 years (ESM Table 3). 
 
3.1 Treatment characteristics  
When patients were administering NPH insulin, 41% were using conventional treatment - in which 
they receive insulin injections twice a day, nutritional assessment and quarterly clinic visits. After six 
months using insulin glargine, this number decreased to 25.9%. Either when using NPH insulin or 
insulin glargine, most patients followed intensive treatment in which they received multiple 
administrations of insulin each day along with extensive educational and medical support. 
 
Carbohydrate counting, reported initially among 21% of patients, increased to 24.8% by the end of 
the study period. When using NPH insulin, 40% of patients used soluble insulin and 13.8% ultra-fast 
analogues. After six months using insulin glargine, the percentage of individuals using soluble 
insulin was 31% and ultrafast-acting insulin analogues 24.8% (ESM Table 4). 
 
49% of patients when using of NPH insulin were injecting three times a day. When using insulin 
glargine, the frequency of administration once a day was 92.6% (ESM Table 4). 
 
The average daily dose of basal insulin ranged from 35.23 ± 15 IU when using NPH insulin to 34.38 
± 15 IU after six months using insulin glargine (p = 0.018). The average daily dose of fast-acting and 
ultra-fast insulin ranged from 14.44 ± 11 IU when using NPH insulin to 14.69 ± 11 IU (p = 0.130) 
after six months using insulin glargine (Table 1). 
 
607 
Excluded by already using insulin 
glargine 
274 
Excluded by having only one 
application process 
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Table 1 -Daily insulin doses in individuals included in the study. 
 
Variable Average 
Standard 
Deviation 
Median Minimum Maximun p - Value 
Daily dose of basal insulin (UI)  
NPH insulin dosage 35.23 15.524 34.00 5 122 0.018* 
Insulin glargine dosage 34.38 15.219 32.00 6 120  
Difference in the daily dose of basal insulin (UI)  
 -0.8460 8.5725 0.00 -70.00 32.00  
Prescribed dose of rapid-acting/ultrafast insulin (UI)  
In NPH insulin use 14.44 11.079 12.00 6 90 0.130 
In insulin glargine use 14.69 10.934 12.00 4 90  
Note: * Statistically significant variation by paired T test.  
 
The doses of insulin glargine in six months of use were evaluated as a function of age. There was a 
statistically significant difference between the mean doses among the various age groups. The post 
hoc analysis showed a statistically significant difference in the mean dose in individuals from 6 to 12 
years compared with other age groups (ESM Table 5). 
 
3.2 Glycemic control  
Comparison of glycated hemoglobin levels before and after six months using insulin glargine 
demonstrated a statistically significant reduction ranging from 8.80 ± 1.98% when using NPH insulin 
to 8.54 ± 1.88% (p = 0.001). The mean difference of glycated hemoglobin before and after six 
months of treatment with insulin glargine was 0.23% (Table 2). 
 
Table 2 - ,QGLYLGXDOV¶+E$1c values 
 
Variable Average 
Standard 
Deviation 
Median Minimum Maximun p - Value 
HbA1c value 
(%) 
 
In NPH insulin use 8.80 1.98 8.52 4.56 16.00 
0.001* 
In insulin glargine use 8.54 1.88 8.30 4.42 17.10 
  
Diference in 
HbA1c(%) 
-0.23 1.937 0.00 -8 9 - 
*Value with a statistically significant difference between groups. Analysis by T test paired. 
 
Individuals¶ glycemic control ranged from 22.6% when using NPH insulin and 26.2% when using 
insulin glargine - Table 3 (In ESM Figure 1, there is documentation of the percentage of people 
achieving glycemic control after 6 months using insulin glargine for different age groups during the 
study). 
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Table 3 - Proportion of individuals with and without blood glucose control. 
 
  Glicemic Control 
 Uncontrolled Controlled 
 N % N % 
In NPH insulin use 449 77.4 131 22.6 
In insulin glargine use 428 73.8 152 26.2 
 
There were no statistically significant differences between the controlled and uncontrolled groups for 
variables including age, history of comorbidities, sex, ethnicity, type of insulin used, type of 
treatment, carbohydrate counting and frequency of use when using NPH insulin and after six months 
using insulin glargine (Table 4). 
 
Table 4 - Univariate analysis of individuals with and without blood glucose control for categorical 
variables. 
 
Variable Uncontrolled Controlled p-Value  
  N % N %  
Comorbities Yes 94 77.0 28 23.0 
0.357 
 No 334 72.9 124 27.1 
Sex Male 211 72.8 79 27.2 
0.571 
 Female 217 74.8 73 25.2 
       
Ethnicity White 151 77 45 23 
0.758  Black 11 73.3 4 26.7 
 Brown 48 72.7 18 27.3 
Type of 
treatment Convencional 110 73.3 40 26.7 0.425 
 Intensive 200 69.7 87 30.3 
Carbohydrate 
counting Yes 99 68.8 45 31.3 0.248 
 No 132 74.6 45 25.4 
Age 06-12 44 67.7 21 32.3 
0.177 
 13-19 71 74.0 25 26.0 
 20-59 279 76.2 87 23.8 
 >=60 34 64.2 19 35.8 
Type of insulin Soluble insulin 130 72.2 50 27.8 
0.385 
 Short-acting analogue 107 74.3 37 25.7 
Frequency of use once a day 394 73.4 143 26.6 
0.414  twice a day 34 79.1 9 20.9 
 3 times a day 0 0 0 0 
 
Factors associated with glycemic control were analyzed after six months using insulin glargine 
through differences between means for continuous variables including: age, age at diagnosis, time 
since diagnosis, basal-acting insulin dose and fast-acting and ultrafast-acting insulin dose. No 
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statistically significant difference was observed between controlled and uncontrolled groups for all 
variables (Table 5). 
 
Table 5 - Univariate analysis of individuals with and without blood glucose control for continuous 
variables. 
 
Variable   Uncontrolled Controlled p-Value * 
Age (years) Average 33.04 33.07 
0.326 
 
Standard 
Deviation 
17.14 18.01 
Age at diagnosis (years) 
 
Average 17.19 18.38 
0.6154 Standard 
Deviation 
13.14 13.31 
Time since diagnosis 
(Years) 
 
Average 15.09 13.97 
0.386 Standard 
Deviation 
12.31 14.01 
Basal-acting insulin 
dose (UI) 
 
Average 35.64 31.07 
0.888 Standard 
Deviation 
15.32 14.50 
Fast/ultrafast-acting 
insulin dose (UI) 
 
Average 15.35 12.51 
0.256 Standard 
Deviation 
12.47 7.38 
Total N 428 152  
Note: * p-value between NPH insulin and insulin glargine controlled. 
At the beginning of the cohort, when 580 patients were using NPH insulin, 449 of had not showed 
good control of the disease and 131 had good blood glycemic control. After six months using insulin 
glargine, only 78 of these patients achieved glycemic control whilst the others (371 patients) 
continued without control (Figure 2). Of the individual patients who had early glycemic control (131 
individuals), 74 patients kept it whilst the others lost it. 
 
Figure 2 - Flowchart of patients and glycaemic control 
 
Beginning cohort 580 individuals were using NPH insulin 
 
 
 
 
 
   
 
4.
131 individuals  with blood 
glycemic control 
449 individuals  without  blood  
glycemic control 
After six months 580 individuals were using insulin glargine 
74 individuals 
with blood 
glycemic control 
57 individuals  
without  blood  
glycemic control 
371 individuals 
without  blood  
glycemic 
control 
78 individuals 
with blood 
glycemic control 
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 Discussion 
 
The analysis of the effectiveness and safety of insulin glargine use in patients with type 1 diabetes is 
an important tool for decision makers, especially where there are considerable differences in 
acquisition costs and resources are limited. 
 
In this cohort of 580 patients, insulin glargine reduced by an average of 0.23% patients¶+E$1c levels 
(Table 2), which is less than considered clinically significant (0.7% to 1%) (20). The same was 
observed in the study by Singh et al. (2009) in which the differences between insulin glargine and 
NPH insulin in terms of HbA1c were considered only marginal among adults with type 1 diabetes 
(weighted mean difference for insulin glargine: -0.11%; 95% CI (-0.21; -0.02%) (21). 
According to the ADA (2015) and Mendes et al. (2010), children aged between 6 and 12 reach 
glycemic control more easily when compared with the other age groups (18,22). Even taking into 
account this influence of age in controlling the disease, this study did not find significant differences 
between the groups with and without glycemic control, in individuals who were using insulin 
glargine (Tables 4 and 5). 
 
When assessing the basal insulin dose, we perceived a slight decrease (2.4%), but significant (p = 
0.018) after six months using insulin glargine (Table 1). This has important clinical consequences 
since this value differs from the insulin glargine manufacturer¶V guidelines (Lantus® brand), which 
states that the average starting dose of insulin glargine is 80% of the NPH insulin dose.  This though 
is in line with Garg et al. (2014) who showed similar results, i.e.  the average dose of insulin glargine 
showed a significant decrease (p = 0.03) when compared with the group that used NPH insulin (23). 
There is a relationship between insufficient guidance for self-care and unsatisfactory adherence to 
treatment with 95% of hypoglycaemic crisis occurrences. Individuals with type 1 diabetes who 
follow intensive treatment also have a 3kg weight gain versus individuals submitted to conventional 
therapy (16).  
 
In a cost-effectiveness study, the results obtained suggest that treatment with insulin analogues is 
associated with a reduction of complications related to diabetes (in other words, more years of 
quality-adjusted life) compared with conventional insulins. However, benefits conferred and 
associated to this reduction complications are not compensatory when we add in the high acquisition 
costs of insulin analogues versus NPH insulin particularly in Brazil (3,24).  
 
Two other studies of effectiveness (5,25) corroborate the data found in this study that the clinical 
evidence does not support the superiority of insulin glargine compared with NPH insulin. Sanches et 
al. (2011) also found no statistically significant reduction of HbA1c when comparing insulin glargine 
and NPH insulin (25). 
 
However, Tricco et al. (2014) in their study, when evaluating the safety, effectiveness and cost-
effectiveness among insulin analogues and NPH insulin in individuals with type 1 diabetes, 
concluded that long-acting insulin analogues are probably superior to NPH insulin, although it is by a 
small difference in HbA1c levels (26). This suggests that patients and their physicians should adapt 
their insulin choice according to preference, cost and accessibility. 
 
Although an economic evaluation has not been the subject of this study, the fact that there are higher 
acquisition costs and lack of therapeutic superiority of insulin glargine over NPH insulin suggests a 
favorable cost-effectiveness relation of the use of NPH insulin, mirroring the findings from our two 
published meta analysis (3,4). Consequently, we believe it is up to managers and decision makers to 
renegotiate therapy costs with insulin glargine since NPH insulin in this and other studies appears to 
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offer the same patient benefits as insulin glargine but with substantially lower acquisition costs 
within public health systems certainly in Brazil. This is similar to the suggestions of Laranjeira et al 
who worked on a discount of 37.5% when calculating the potential budget impact of insulin glargine 
used in restricted cases (27).  
 
We acknowledge though that there are limitations with this study design. Firstly, we confined our 
analysis to patients within Minas Gerais. However, this is one of the most populated regions in Brazil 
with similar age and sex characteristics to other regions in Brazil, representing well Brazil as a 
whole. Secondly, only patients with completed and approved report forms for insulin glargine where 
included, which limited some of the analysis. The variable reporting of comorbidities was also an 
optional field in the report. The fact that the individuals with type 1 diabetes did not report the 
presence of comorbidities (79% of individuals) does not mean they do not have these. It wasn't 
possible to also evaluate the reduction of hypoglycaemic episodes from the data entered onto the 
SUS database. In addition, the use of a retrospective data limits access to important data. The 
conditions of observational studies are also not under the control of the investigator, and the 
researcher does not intervene in the allocation of participants. This is a characteristic of this type of 
design. We tried, however, to minimize possible biases by confirming the results through laboratory 
tests and reviews of medical reports where we could. Despite these limitations, we believe our 
findings are robust giving direction to Ministry of Health personnel in Minas Gerais and Brazil to 
potentially re-negotiate prices for insulin glargine. Prices of insulin glargine may start falling anyway 
now that biosimilars have been approved in the US and Europe (28,29). 
 
It is noteworthy that the evaluation of insulin glargine for the treatment of type 1 diabetes 
demonstrated in this study that analog insulins were not superior to insulin NPH in terms of their 
effectiveness. These results impact on the likely scenario of the new analogues such as insulin 
degludec. Having said this, recent studies have indicated insulin degludec is a more cost effective 
option than insulin glargine [30,31]. However, studies in patients in routine clinical care are needed 
that directly compare the effectiveness of these analogues, as well as their effectiveness versus NPH 
insulins, to conclude about their cost-effectiveness within universal healthcare systems such as 
Brazil. We await further evidence.  
 
5. Conclusion  
 
Insulin glargine showed no clinical advantage over NPH insulin in reducing HbA1c values and 
glycemic control in our cohort study, confirming the findings from our previous meta analyses. 
Whilst insulin glargine has an appreciably higher cost than NPH insulin, we believe it is mandatory 
for health authority personnel to review the pricing strategy of insulin glargine in Brazilian States 
that provide insulin free of charge to their citizens and renegotiate prices where pertinent in order to 
ensure the sustainability of public health systems. The availability of biosimilar insulin glargine may 
facilitate this in Brazil 
 
Summary Points 
x This is an observational, longitudinal, analytical and prospective study that evaluates the 
comparative clinical effectiveness of two insulins for the treatment of type 1 diabetes. This type 
of design is useful to generate evidence about the benefits and harms of the different 
interventions in routine clinical care (real-world) 
x The cost of medicines, specifically insulin glargine, has grown considerably in Brazil in recent 
years, which raises the need for rationalization and optimization of financial resources in order to 
guarantee the sustainability of the health system as well as access to an effective and safe therapy 
to people with diabetes. 
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x This review of clinical data did not show any additional clinical benefit in type 1 diabetes 
patients using insulin glargine in relation to NPH insulin, confirming the results from other 
previous studies and reviews. 
x 7KHUHDSSHDUHGWREHQRDVVRFLDWLRQEHWZHHQJO\FHPLFFRQWURODQGLQGLYLGXDO¶VFKDUDFWHULVWLFVRU
treatment between patients receiving NPH insulin and then switched to insulin glargine. 
x Insulin glargine reduced by an average of 0.23SDWLHQWV¶+E$FZKLFKLVOHVVWKDQFRQVLGHUHG
clinically significant (0.7% to 1%). The limited benefits conferred are not compensated by the 
high acquisition cost of insulin analogues vs NPH insulin in Brazil 
x There are higher costs and lack of therapeutic superiority of insulin glargine over NPH insulin 
suggests a favorable cost-effectiveness for NPH insulin vs, insulin glargine  
x This review provides a basis for health system managers to maintain or exclude insulin glargine 
from the reimbursed list of medicines offered for the treatment of diabetes whilst there is still 
appreciable differences in acquisition costs between the two insulins 
x It is up to managers and decision makers to renegotiate therapy costs, or even discuss the 
possibility of disinvestment, once proven that NPH insulin offers the same benefits as insulin 
glargine but with substantially lower costs within public health systems. 
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Figure  1 - Glycemic control after 6 months using glargine analog, by age group. 
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Table 1 ± Inclusion criteria to dispensing program of glargine analog in Clinical Protocol and 
Therapeutic Guidelines (1). 
 
1. The diagnosis of diabetes mellitus type 1 and LADA should be proven through detailed 
medical reports and supplementary examinations: fasting glucose and / or random, confirmed 
by a second dose and glycated hemoglobin. Other examinations may be required where there 
continue to be doubts as to the correct classification applicable to the patient. 
2. It is necessary to document the persistence of poor glycemic control and the incidence of 
severe hypoglycemia without warning signs. The evidence of poor glycemic control will be 
made by the demonstration of laboratory tests (glycated hemoglobin and blood glucose levels) 
recorded 2 times at intervals of four months between tests. For the purposes specified in this 
protocol, it is understood that poor glycemic control is the persistence of glycohemoglobin with 
more than 2 percentage points above the normal test upper limit. 
3. Patients who suffer from severe hypoglycemia (less than 50 mg / dl) for 2 or 3 proven 
episodes by laboratory examination and / or hospital care report this condition in at least two 
separate occasions in the past six months, they may be included in the same program without 
the confirmation of the occurrence of persistent hyperglycemia, as defined in item 2. 
4. Be older than 6 years. 
5. Patients who have been administered glargine analog for more than a year, which have not 
yet been included in the glargine dispensing program, and to monitor glycemic control - should 
have record of severe hypoglycemic episodes as described in items 2 and 3. 
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Table 2 - Patients characteristics (N = 580). Minas Gerais, Brazil 
 
Variable N (%) 
Sex Male 290 50 
 
Female 290 50 
Ethnicity White 196 33.8 
 
Black 15 2.6 
 
Brown 66 11.4 
 
Uninformed 303 52.2 
Age 06-12 65 11.2 
 
13-19 96 16.6 
 
20-59 366 63.1 
 
>=60 53 9.1 
Report of comorbidities 
Yes 122 21 
No 458 79.0 
 
Table 3 - Descriptive statistics of patients included in the study. 
 
Variable Average  
Standard 
Deviation 
Median Minimum Maximum 
Age (years) 33.04 17.357 31.00 6 75 
Age at diagnosis 
(years) 
17.50 13.185 13.50 0 65 
Diagnosis time 
(years) 
14.80 12.776 12.00 1 57 
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Table 4 - Characteristics of the treatment used (N = 580). Minas Gerais, Brazil. 
 
Variável N (%) 
Type of Treatment Conventional 150 25.9 
 
Intensive 287 49.5 
 
Uninformed 143 24.7 
Carbohydrates 
Counting 
Yes 144 24.8 
 
No 177 30.5 
 
Uninformed 259 44.7 
Insulin type of 
fast/ultrafast acting 
Regular 180 31.0 
Short-acting analog  144 24.8 
 
Uninformed 256 44.1 
 
Total  580 100.0 
Frequency once a day 
537 92.6 
twice a day 43 7.4 
 3 times a day 580 100.0 
 
Table 5 - Dose Analysis of analog glargine in different age groups. 
 
Variable N Average 
Standard 
Deviation 
Minimum Maximum p-Value 
Dosage (UI)       
0,000* 
6 a 12 65 19.18 10.927 6 58 
13 a 19 96 33.53 13.643 2 60 
20 a 59 366 37.24 14.925 6 120 
 53 35.53 13.584 10 80 
Note: * Statistically significant difference. Post hoc analysis was performed using the Tukey test. 
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